Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized ewing sarcoma: A report from the children's oncology group

Journal of Clinical Oncology

Volumn 30, Issue 33, 2012, Pages 4148-4154

  Womer, Richard B ^a   West, Daniel C ^b   Krailo, Mark D ^c   Dickman, Paul S ^d   Pawel, Bruce R ^a   Grier, Holcombe E ^e   Marcus, Karen ^e   Sailer, Scott ^f   Healey, John H ^g   Dormans, John P ^a   Weiss, Aaron R ^h  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d PHOENIX CHILDREN'S HOSPITAL   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADOLESCENT; ADULT; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CATHETER INFECTION; CHILD; COLITIS; CONTROLLED STUDY; DRUG DOSE INTENSIFICATION; DRUG EFFICACY; EVENT FREE SURVIVAL; EWING SARCOMA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOKALEMIA; INFANT; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHARYNGITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STOMATITIS; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE; TYPHLITIS; VOMITING; WOUND INFECTION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; HUMANS; IFOSFAMIDE; INFANT; MIDDLE AGED; PROSPECTIVE STUDIES; SARCOMA, EWING; VINCRISTINE; YOUNG ADULT;

EID: 84869447819     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.5703     Document Type: Article

References (25)

1. Nesbit ME Jr, Gehan EA, Burgert EO Jr, et al: Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: A long-term follow-up of the First Intergroup study. J Clin Oncol 8:1664-1674, 1990
2. Smith MA, Ungerleider R, Horowitz ME, et al: Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 83:1460-1470, 1991
3. Smith MA: The impact of doxorubicin dose intensity on survival of patients with Ewing's sarcoma. J Clin Oncol 9:889-891, 1991
4. Burgert EO Jr, Nesbit ME, Garnsey LA, et al: Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup study IESS-II. J Clin Oncol 8:1514-1524, 1990
5. Grier HE, Krailo M, Tarbell N, et al: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 348:694-701, 2003
6. Granowetter L, Womer RB, Devidas M, et al: Comparison of dose-intensified and standard dose chemotherapy for the treatment of non-metastatic Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET) of bone and soft tissue: A Pediatric Oncology Group-Children's Cancer Group phase III trial. Proceedings of the International Society of Pediatric Oncology XXXIII Meeting, Brisbane. Med Pediatr Oncol 37:172, 2001 (abstr)
7. Womer RB, Daller RT, Fenton JG, et al: Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcoma and soft tissue sarcomas in children. Eur J Cancer 36:87-94, 2000
8. Pocock S: Clinical Trials: A Practical Approach. New York, NY, John Wiley & Sons, 1983, pp 82-84
9. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
10. Kalbfleisch J, Prentice R: The Statistical Analysis of Failure Time Data. New York, NY, John Wiley & Sons, 2002
11. Prentice R, Kalbfleisch J, Peterson A, et al: The analysis of failure times in the presence of competing risks. Biometrics 34:541-554, 1978
12. Fine J, Gray R: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
13. Bishop Y, Feinberg S, Holland P: Discrete Multivariate Analysis. Cambridge, MA, MIT Press, 1975
14. Granowetter L, Womer R, Devidas M, et al: Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: A Children's Oncology Group study. J Clin Oncol 27:2536-2541, 2009
15. Wexler LH, Weaver-McClure L, Steinberg SM, et al: Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy. J Clin Oncol 14:901-910, 1996
16. Norton L: Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 24:S10-3-S10-10, 1997 (suppl)
17. Woods WG, Kobrinsky N, Buckley JD, et al: Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group. Blood 87:4979-4989, 1996
18. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003
19. Lewis IJ, Nooij MA, Whelan J, et al: Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: A randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 99:112-128, 2007
20. Sculier JP, Paesmans M, Lecomte J, et al: A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics. Br J Cancer 85:1444-1451, 2001
21. Farewell V: Historical controls. Pediatrics 70:145-147, 1982
22. Farewell V, D'Angio G: A simulated study of historical controls using real data. Biometrics 37:169-176, 1981
23. Morales-Arias J, Meyers PA, Bolontrade MF, et al: Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: Potential consequences of granulocyte-colony-stimulating factor administration. Cancer 110:1568-1577, 2007
24. Foote M, Boone T: Biopharmaceutical drug development: A case history, in Walsh G, Murphy B (eds): Biopharmaceuticals, an Industrial Perspective. New York, NY, Kluwer Academic Publishers/Springer, 1999
25. Borinstein SC, Pollard J, Winter L, et al: Pegfilgrastim for prevention of chemotherapy-associated neutropenia in pediatric patients with solid tumors. Pediatr Blood Cancer 53:375-378, 2009